Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Gut microbiota in Alzheimer's disease: Understanding molecular pathways and potential therapeutic perspectives
Publication Year: 2025 Source: Ageing Res Rev PMID: 39800223
Accumulating evidence suggests that gut microbiota (GM) plays a crucial role in Alzheimer's disease (AD) pathogenesis and progression. This narrative review explores the complex interplay between GM, the immune system, and the central nervous system in AD. We discuss mechanisms through which GM dysbiosis can compromise intestinal barrier integrity, enabling …
Impact of 5-Aminosalicylic Acid on Ustekinumab in Inflammatory Bowel Disease: A Retrospective Medical Claims Analysis
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 39800762 DOI: 10.1093/ibd/izaf001
BACKGROUND: The efficacy of 5-aminosalicylic acid (5-ASA) in combination with advanced therapies (ADTs), particularly ustekinumab (UST), for the treatment of inflammatory bowel disease (IBD) remains unclear. METHODS: This retrospective cohort analysis used data from the Medical Data Vision database, including patients with ulcerative colitis (UC) and Crohn's disease (CD) who …
Segmental colectomy versus total proctocolectomy for ulcerative colitis: A systematic review and meta-analysis
Publication Year: 2025 Source: Colorectal Dis PMID: 39800862
AIM: Total proctocolectomy (TPC) is the standard of care for patients with ulcerative colitis (UC) and dysplasia not amenable to endoscopic management. However, the risks of an extensive resection may outweigh the benefits in high-risk surgical patients. Therefore, we performed a systematic review and meta-analysis to assess postoperative outcomes between …
Guselkumab: A New Therapeutic Option for the Treatment of Moderately to Severely Active Ulcerative Colitis
Publication Year: 2025 Source: Ann Pharmacother PMID: 39800899
OBJECTIVE: To summarize the evidence and pharmacologic profile of guselkumab for moderate to severe ulcerative colitis (UC). DATA SOURCES: A PubMed search from inception to end of October 2024 using keywords guselkumab, UC, and interleukin (IL) was conducted. Additional information was obtained from abstracts and package insert. STUDY SELECTION AND …
A Nitrate/Nitrite Biosensor Designed with an Antiterminator for In Vivo Diagnosis of Colitis Based on Bacteroides thetaiotaomicron
Publication Year: 2025 Source: ACS Synth Biol PMID: 39801064
Bacteroides thetaiotaomicron is a common microorganism in the human gut that has been linked to health benefits. Furthermore, it is an emerging synthetic biology chassis with the potential to be modified into diagnostic or therapeutic engineered probiotics. However, the absence of biological components limits its further applications. In this study, …
Machine Learning-Assisted High-Throughput Screening of Nanozymes for Ulcerative Colitis
Publication Year: 2025 Source: Adv Mater PMID: 39801185
Ulcerative colitis (UC) is a chronic gastrointestinal inflammatory disorder with rising prevalence. Due to the recurrent and difficult-to-treat nature of UC symptoms, current pharmacological treatments fail to meet patients' expectations. This study presents a machine learning-assisted high-throughput screening strategy to expedite the discovery of efficient nanozymes for UC treatment. Therapeutic …
Expanding the Role of Mindfulness in IBD Care: Bridging Psychological Well-being and Disease Management
Publication Year: 2025 Source: Actas Esp Psiquiatr PMID: 39801403 DOI: 10.62641/aep.v53i1.1836
No Abstract
Advanced polymeric systems for colon drug delivery: from experimental models to market applications
Publication Year: 2025 Source: Soft Matter PMID: 39801430
In recent years, nano and micro drug delivery systems targeting the colon have gained more attention due to increasing interest in treating colon diseases such as colorectal cancer and inflammatory bowel disease, i.e., Crohn's disease and ulcerative colitis. Usually, nanocarriers are exploited for their enhanced permeability properties, allowing higher penetration …
Relationship Between Patient Demographics and Biologic Therapy Use in Inflammatory Bowel Disease. A Single Center Cross-Sectional Study
Publication Year: 2025 Source: JGH Open PMID: 39802136 DOI: 10.1002/jgh3.70092
INTRODUCTION: Biologic therapies treat patients with moderate to severe inflammatory bowel disease (IBD). This study aims to investigate the demographics of biologic therapy use and its association with patient characteristics, a topic that has not yet been thoroughly assessed in our region. METHODS: Electronic health record data from June 1, …
Impact of pericarditis on cardiovascular complications and healthcare utilization in patients with inflammatory bowel disease: a National Inpatient Sample study
Publication Year: 2025 Source: Ann Gastroenterol PMID: 39802295 DOI: 10.20524/aog.2024.0931
BACKGROUND: Inflammatory bowel disease (IBD), which affects over 2.3 million people in the USA, involves chronic gut inflammation and can lead to cardiovascular complications, including pericarditis. Whether pericarditis in IBD patients is caused by medication, or by the disease itself, remains unclear. Our study aimed to determine the prevalence of …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide